Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the GI tract and is a heterogeneous disease that is primarily driven by activating mutations in receptor tyrosine kinases.1,2 KIT and PDGFRA mutations are the drivers of ~85% of GIST and keep the kinase in the active state, causing uncontrolled cell proliferation and/or cell survival.2-4
In localized disease, the primary treatment includes surgery (resectable GIST) and neoadjuvant therapy to reduce tumor size, maximize resectability, and avoid multi-visceral resection.5,6 In metastatic disease, tyrosine kinase inhibitors are recommended.6
GIST Materials
INSIGHT Trial Overview
SIUU Initiatives
- Heinrich MC, et al. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 2024;30:498-506.
Zalcberg JR, et al. Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: an analysis of the INVICTUS study. Oncologist. 2021;26(11):e2053-e2060.
- https://academic.oup.com/oncolo/article/26/11/e2053/6508781?login=true
- Corresponding one pager
George S, et al. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumor. Eur J Cancer. 2021;155:236-244.
References
1) Corless CL, et al. Nat Rev Cancer. 2011;11(12):865-878.
2) Li K, et al. Oncotarget 2017;8(36):60589-60604.
3) Antonescu CR, et al. Clin Cancer Res. 2005;11(11):4182–4190.
4) Zhao X, Yue C. J Gastrointest Oncol. 2012;3(3):189–208.
5) Gold JS, et al. Ann Surg. 2006;244(2):176-184.
6) Huang WK, et al. Curr Treat Options Oncol. 2022;23(9):1303-1319.